Evotec SE stock (DE0005664809): Steady FY 2025 results amid US expansion

Evotec SE reported fiscal year 2025 results on March 27, 2026, highlighting steady progress in partnerships with major pharma firms. Shares traded at 8.50 EUR on Xetra on May 13, 2026.

Evotec SE, a leading provider of drug discovery and development services, published its fiscal year 2025 results on March 27, 2026, showing steady progress in key partnerships with pharmaceutical companies, according to Evotec IR as of 03/27/2026. The Hamburg-based firm continues to expand its US presence, appealing to American investors via its OTC listing. Shares traded at approximately 8.50 EUR on Xetra on May 13, 2026, according to ad-hoc-news.de as of 05/13/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Evotec SE
• Sector/industry: Biotechnology / Drug Discovery Services
• Headquarters/country: Hamburg, Germany
• Core markets: US, Europe
• Key revenue drivers: Integrated drug discovery, development partnerships
• Home exchange/listing venue: Xetra (EVT.DE)
• Trading currency: EUR

Evotec SE: core business model

Evotec SE operates an asset-agnostic drug discovery and development platform, partnering with big pharma and biotech companies to advance novel therapies. The company integrates industrial processes with technologies like AI-driven target identification and high-throughput screening. Headquartered in Hamburg, it employs over 5,000 scientists across sites in Europe and the US, including key facilities in Princeton, New Jersey.

Main revenue and product drivers for Evotec SE

Evotec SE generates revenue primarily through integrated drug discovery and development partnerships. These alliances with major pharmaceutical firms drive the bulk of income, as highlighted in the fiscal year 2025 results published on March 27, 2026, according to Evotec IR as of 03/27/2026. The firm's platform supports end-to-end services from target identification to clinical candidates.

Why Evotec SE matters for US investors

Evotec SE's OTC listing under EVTKY offers US investors direct access to a European biotech services leader without ADR complexities. With facilities in Princeton, New Jersey, the company taps into the US biotech outsourcing trend, providing exposure to pharma R&D spending amid domestic market volatility.

Conclusion

Evotec SE maintains operational resilience through diversified partnerships and US expansion, as shown in its fiscal year 2025 results from March 27, 2026. The stock's steady trading reflects a challenging yet opportunity-rich biotech environment. Investors track its role in global drug discovery for long-term trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.